ABOS
Companies
NASDAQ
Acumen Pharmaceuticals Inc.
Health Care
$1.20
-$0.52 (-30.52%)
Price Chart
Overview
About ABOS
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Market Cap
$157.4M
Volume
174.5K
Avg. Volume
244.2K
P/E Ratio
-0.68627447
Dividend Yield
0.00%
Employees
26.0
Company Information
Latest News for ABOS
Risk & Correlation Analysis
Market Correlation
0.84
Moderate Correlation
Volatility
High (0.73)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ABOS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$157.4M
Volume174.5K
P/E Ratio-0.69
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025